Perforated intravenous catheter design is acceptable for the administration of contrast-enhanced computed tomography administration in cancer patients: Results of a pilot randomised controlled trial

Author:

Gavin Nicole C123ORCID,Wignall Elizabeth4,Marsh Nicole135,Marquart Louise67,Dobeli Karen L4,O’Brien Catherine45,Verderosa Anthony D8,Totsika Makrina8,Keogh Samantha135ORCID

Affiliation:

1. School of Nursing and Centre for Healthcare Transformation, Queensland University of Technology, Kelvin Grove, QLD, Australia

2. Cancer Care Services, Royal Brisbane and Women’s Hospital, Herston, QLD, Australia

3. Alliance for Vascular Access Teaching and Research (AVATAR), School of Pharmacy and Medical Sciences, Griffith University, Nathan, QLD, Australia

4. Department of Medical Imaging, Royal Brisbane and Women’s Hospital, Herston, QLD, Australia

5. Nursing and Midwifery Research Centre, Royal Brisbane and Women’s Hospital, Herston, QLD, Australia

6. School of Public Health, University of Queensland, Herston, QLD, Australia

7. Queensland Institute of Medical Research Berghofer Medical Research Institute, Herston, QLD, Australia

8. School of Biomedical Sciences and Centre for Immunology and Infection Control, Queensland University of Technology, Kelvin Grove, QLD, Australia

Abstract

Background: Optimising first time success of peripheral intravenous catheter (PIVC) insertion and reducing intravenous (IV) complications in cancer patients undergoing contrast-enhanced computed tomography (CT) is vital to ensure vascular access preservation and diagnostic accuracy. The aim of this study was to test the feasibility of a randomised controlled trial (RCT) evaluating a novel perforated PIVC compared to a standard PIVC. Methods: A single centre, parallel-group, pilot RCT was conducted between March and May 2020. Adult participants diagnosed with cancer were randomised to a non-perforated PIVC (standard care) or a PIVC with a novel perforated design (intervention) for the administration of IV contrast. There were two primary outcomes: (1) feasibility of an adequately powered RCT with pre-established criteria; and (2) all-cause PIVC failure. Secondary outcomes included: first insertion success, modes of PIVC failure, dwell time, contrast injection parameters (volume and injection rate), contrast enhancement, radiographer satisfaction and adverse events. Results: Feasibility outcomes were met, except for eligibility (⩾90%) and recruitment (⩾90%). In total, 166 participants were screened, 128 (77%) were eligible and of these 101/128 (79%) were randomised; 50 to standard care and 51 to intervention. First time insertion rate was 94% (47/50) in standard care and 90% (46/50) in intervention. The median dwell time was 37 minutes (interquartile range (IQR): 25–55) in standard care and 35 minutes (IQR: 25–60) in the intervention group. There was one PIVC failure, a contrast media extravasation, in the intervention group (1/51; 2%). The desired contrast injection rate was not achieved in 4/101 (4%) of participants; two from each group. Radiographers were satisfied with the contrast flow rate. Conclusions: This pilot RCT suggests perforated PIVCs provide expected flow rate, with no evidence of differences in contrast enhancement to non-perforated PIVCs. The feasibility of conducting a larger powered RCT was demonstrated.

Funder

Metro North Health

Publisher

SAGE Publications

Subject

Nephrology,Surgery

Reference30 articles.

1. MRI and CT contrast media extravasation

2. Tang VC, Eastgate P, Prior M, et al. Audit of contrast-media extravasation in a tertiary hospital. 2017 ASM / R-0063, European Society of Radiology, 2017.

3. Intravenous contrast medium extravasation: systematic review and updated ESUR Contrast Media Safety Committee Guidelines

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3